Seres Therapeutics and Nestlé Health Science Present P-III Study (ECOSPOR IV) Results Vowst for Prevention of Recurrence of C. Difficile Infection at DDW 2023
Shots:
- The P-III open-label study (ECOSPOR IV) evaluating Vowst, the US FDA-approved orally administered microbiota-based therapeutic to prevent recurrence in 263 patients, showed that 91.3% of patients achieved clinical response @8wks. & 94.6% maintained a response through 24wk. in the overall population
- In patients with a first & ≥2 recurrences, 93.5% & 90.3% achieved a clinical response @8wk.; 94.4% & 94.6% maintained the response through 24wks., respectively
- In a post hoc subgroup analysis by selecting baseline characteristics, rates of rCDI were observed @8wk. across all patients (8.7%), patients with first recurrence (6.5%) vs ≥2 recurrences (9.7%). The results were published in JAMA Network Open
Ref: Businesswire | Image: Seres Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
